Cyclerion Therapeutics Inc (NAS:CYCN)

$ 2.7 0.41 (17.98%) Market Cap: 6.75 Mil Enterprise Value: 1.05 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 47/100

Cyclerion Therapeutics Inc Clinical Data Update from Study of CY6463 in CIAS Webinar Transcript
Jul 28, 2022
Cyclerion Therapeutics Inc Call to Discuss CY6463 MELAS Clinical Data Transcript
Jun 28, 2022
Cyclerion Therapeutics Inc Pipeline Update Webinar Corporate Call Transcript
Apr 27, 2021
Cyclerion Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Cyclerion Therapeutics, Inc. - Special Call Transcript
Oct 14, 2020
Cyclerion Therapeutics, Inc. - Special Call Transcript
Jul 09, 2020
Cyclerion Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 16, 2020
Cyclerion Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Cyclerion Therapeutics, Inc. - Special Call Transcript
Oct 30, 2019
Cyclerion Therapeutics Inc Investor Webcast Event Transcript
Sep 17, 2019
Cyclerion Therapeutics Inc Corporate Overview Call Transcript
May 13, 2019

Cyclerion Therapeutics, Inc. - Special Call Transcript

Oct 14, 2020 / 12:30PM GMT

Release Date Price: $67 (-52.95%)

Transcript

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the IW-6463 clinical program top line results update conference call. (Operator Instructions)

I would now like to hand the conference to your speaker today, Bill Huyett, Chief Financial Officer. Please go ahead, sir.

William Huyett

Cyclerion Therapeutics, Inc. - CFO

Thank you, Jorel. Good morning. Thank you for joining us today. You will have seen our 2 press releases that crossed the wire earlier today. This morning, we'll be discussing the exciting top line findings from Cyclerion's translational pharmacology study, IW-6463, for treating CNS disorders.

From Cyclerion, Peter Hecht, our CEO; Chris Wright, our Chief Medical Officer; and Cheryl Gault, our Strategy and Business development Leader, will cover further remarks. Dr. Andrew Budson, an independent expert in cognitive and behavioral neurology, will also participate in the call.

We'll be reviewing slides that are available from the Investor and Media section of our website during these remarks and encourage you

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.